Benedicte Deau

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA.

Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA.

Journal: HemaSphere

Published: November 25, 2024

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 25, 2024

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

Journal: British journal of haematology

Published: February 06, 2023

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Journal: Pharmaceutics

Published: June 29, 2022

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.

Journal: Haematologica

Published: May 30, 2022

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).

Journal: British journal of haematology

Published: March 01, 2022

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.

Journal: Haematologica

Published: July 05, 2021

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 21, 2021

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 29, 2020

Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.

Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.

Journal: British journal of haematology

Published: March 06, 2019

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 12, 2019

The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.

The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.

Journal: European journal of haematology

Published: April 04, 2018

Showing 1-12 of 30

Last Updated: 09/26/2026